AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2019

Mar 7, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2019-03-05

Reporting Person: Biller Scott (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-03-05	Common stock	M	428	$31.64	Acquired	26939	Direct
2019-03-05	Common stock	M	2572	$39.76	Acquired	29511	Direct
2019-03-05	Common stock	S	200	$66.45	Disposed	29311	Direct
2019-03-05	Common stock	S	2600	$67.73	Disposed	26711	Direct
2019-03-05	Common stock	S	200	$68.22	Disposed	26511	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-03-05	Stock option (right to buy)	$31.64	M	428	Disposed	2024-03-04	Common stock (428)	Direct
2019-03-05	Stock option (right to buy)	$39.76	M	2572	Disposed	2026-02-15	Common stock (2572)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common stock	53059	Indirect

Footnotes

F1: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $66.05 to $66.85. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F4: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $67.14 to $68.13. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F5: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $68.14 to $68.30. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F6: Shares held by a spousal lifetime access trust, of which the reporting person's wife is the trustee.

F7: This option was granted on March 5, 2014. The shares underlying this option vest as to 25% of the shares on March 5, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter.

F8: This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter.